DK1740569T3 - Imidazole derivatives as TAF1α inhibitors - Google Patents

Imidazole derivatives as TAF1α inhibitors

Info

Publication number: DK1740569T3
Authority: DK; Denmark
Prior art keywords: taf1α; inhibitors; imidazole derivatives; imidazole; derivatives
Prior art date: 2004-04-22

Application number

DK05731221T

Other languages

Danish (da)

Inventor

Christopher Kallus

Holger Heitsch

Andreas Lindenschmidt

Sven Grueneberg

Hauke Szillat

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-07

Publication date

2008-06-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1740569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-07 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2008-06-02 Application granted granted Critical

2008-06-02 Publication of DK1740569T3 publication Critical patent/DK1740569T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK05731221T 2004-04-22 2005-04-07 Imidazole derivatives as TAF1α inhibitors DK1740569T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004020186A DE102004020186A1 (en)	2004-04-22	2004-04-22	Heterocyclyl acetic acids as inhibitors of TAFla
PCT/EP2005/003630 WO2005105781A1 (en)	2004-04-22	2005-04-07	Imidazole derivatives used as tafia inhibitors

Publications (1)

Publication Number	Publication Date
DK1740569T3 true DK1740569T3 (en)	2008-06-02

Family

ID=34964308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05731221T DK1740569T3 (en)	2004-04-22	2005-04-07	Imidazole derivatives as TAF1α inhibitors

Country Status (34)

Country	Link
EP (2)	EP1740569B1 (en)
JP (1)	JP4939401B2 (en)
KR (1)	KR101162047B1 (en)
CN (1)	CN100572376C (en)
AR (1)	AR053302A1 (en)
AT (2)	ATE523505T1 (en)
AU (1)	AU2005238144B2 (en)
BR (1)	BRPI0510159A (en)
CA (1)	CA2563401C (en)
CR (1)	CR8650A (en)
CY (1)	CY1108087T1 (en)
DE (2)	DE102004020186A1 (en)
DK (1)	DK1740569T3 (en)
EC (1)	ECSP066941A (en)
ES (1)	ES2299026T3 (en)
HR (1)	HRP20080099T3 (en)
IL (1)	IL178672A (en)
MA (1)	MA28543B1 (en)
MY (1)	MY140903A (en)
NI (1)	NI200600217A (en)
NO (1)	NO20065320L (en)
NZ (1)	NZ550757A (en)
PE (1)	PE20060172A1 (en)
PL (1)	PL1740569T3 (en)
PT (1)	PT1740569E (en)
RS (1)	RS50553B (en)
RU (1)	RU2375356C2 (en)
SI (1)	SI1740569T1 (en)
TN (1)	TNSN06341A1 (en)
TW (1)	TWI359016B (en)
UA (1)	UA87306C2 (en)
UY (1)	UY28868A1 (en)
WO (1)	WO2005105781A1 (en)
ZA (1)	ZA200607668B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2104497T3 (en) *	2006-12-06	2015-05-26	Sanofi Sa	SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CL2008000429A1 (en) *	2007-02-13	2008-08-18	Schering Corp	COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AFFECTIONS ASSOCIATED WITH ALFA2C ADRENERGIC RECEPTORS, SUCH AS CONGESTION ASSOCIATED WITH RHINITIS, POLIPOS, COLD
AU2008279447A1 (en) *	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) *	2008-02-21	2010-12-22	Sanofi-Aventis	Covalently binding imaging probes
BRPI0913349A2 (en) *	2008-06-06	2015-11-24	Sanofi Aventis	macrocyclic urea and sulfamide derivatives as tafia inhibitors
NZ592764A (en)	2008-10-29	2012-08-31	Taisho Pharmaceutical Co Ltd	Compound having tafia inhibitory activity
US8865906B2 (en) *	2009-05-15	2014-10-21	Sanofi	Process for the preparation of a compound useful as an inhibitor of TAFIa
FR2947266B1 (en) *	2009-06-26	2011-06-17	Servier Lab	NOVEL 2-MERCAPTOCYCLOPENTANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CN102666553B (en)	2009-10-01	2015-05-06	赛马拜制药公司	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2548872B1 (en)	2010-03-18	2016-09-28	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
SI2548871T1 (en)	2010-03-18	2017-10-30	Daiichi Sankyo Company, Limited	Cycloalkyl-substituted imidazole derivative
CN103201269A (en)	2010-11-11	2013-07-10	赛诺菲	Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9102657B2 (en) *	2011-11-25	2015-08-11	Sanofi	Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (en)	2011-11-25	2013-05-30	Sanofi	Salt of (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl) ethyl propionate
WO2013076178A1 (en)	2011-11-25	2013-05-30	Sanofi	Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2805705B1 (en)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
CN105263928A (en)	2013-06-10	2016-01-20	赛诺菲	Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en)	2016-03-29	2019-11-20	Daiichi Sankyo Company, Limited	THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
CA3032432A1 (en)	2016-08-03	2018-02-08	Charles A. Mcwherter	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9917112A (en) *	1998-12-24	2002-01-29	Fujisawa Pharmaceutical Co	Imidazole compounds and their medicinal use
WO2003013526A1 (en) *	2001-08-08	2003-02-20	Merck & Co. Inc.	Anticoagulant compounds
JP2005516972A (en)	2002-01-22	2005-06-09	ファイザー・インク	3- (imidazolyl) -2-aminopropionic acid used as TAFI-A inhibitor for the treatment of thrombotic diseases

2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/en not_active Withdrawn
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/en not_active Application Discontinuation
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 AT AT07017340T patent/ATE523505T1/en active
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/en active Application Filing
- 2005-04-07 ES ES05731221T patent/ES2299026T3/en not_active Expired - Lifetime
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/en not_active Expired - Lifetime
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/en unknown
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/en not_active Expired - Fee Related
- 2005-04-07 EP EP05731221A patent/EP1740569B1/en not_active Expired - Lifetime
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/en not_active Application Discontinuation
- 2005-04-07 DK DK05731221T patent/DK1740569T3/en active
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 EP EP07017340A patent/EP1864979B1/en not_active Expired - Lifetime
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/en not_active Expired - Lifetime
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/en not_active Expired - Fee Related
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/en unknown
- 2005-04-07 PT PT05731221T patent/PT1740569E/en unknown
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/en not_active IP Right Cessation
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 SI SI200530185T patent/SI1740569T1/en unknown
- 2005-04-07 PL PL05731221T patent/PL1740569T3/en unknown
- 2005-04-07 AT AT05731221T patent/ATE386737T1/en active
- 2005-04-20 AR ARP050101556A patent/AR053302A1/en not_active Application Discontinuation
- 2005-04-20 TW TW094112493A patent/TWI359016B/en not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-22 UY UY28868A patent/UY28868A1/en unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/en unknown
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/en unknown
- 2006-09-22 CR CR8650A patent/CR8650A/en unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/en unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/en not_active Application Discontinuation
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/en unknown

Also Published As

Publication number	Publication date
PT1740569E (en)	2008-03-31
DE102004020186A1 (en)	2005-11-17
EP1740569B1 (en)	2008-02-20
KR101162047B1 (en)	2012-07-04
WO2005105781A1 (en)	2005-11-10
CR8650A (en)	2007-12-04
RU2006141246A (en)	2008-06-10
MA28543B1 (en)	2007-04-03
UA87306C2 (en)	2009-07-10
BRPI0510159A (en)	2007-10-02
PL1740569T3 (en)	2008-07-31
PE20060172A1 (en)	2006-03-31
RU2375356C2 (en)	2009-12-10
TNSN06341A1 (en)	2008-02-22
EP1864979A1 (en)	2007-12-12
JP2007533672A (en)	2007-11-22
IL178672A0 (en)	2007-02-11
CA2563401C (en)	2012-08-07
ES2299026T3 (en)	2008-05-16
CN100572376C (en)	2009-12-23
EP1740569A1 (en)	2007-01-10
HRP20080099T3 (en)	2008-03-31
RS50553B (en)	2010-05-07
TW200602325A (en)	2006-01-16
KR20070007346A (en)	2007-01-15
JP4939401B2 (en)	2012-05-23
ATE386737T1 (en)	2008-03-15
MY140903A (en)	2010-01-29
NI200600217A (en)	2008-06-17
NO20065320L (en)	2007-01-12
NZ550757A (en)	2010-06-25
CY1108087T1 (en)	2014-02-12
HK1101823A1 (en)	2007-10-26
ZA200607668B (en)	2008-03-26
CN1950357A (en)	2007-04-18
AR053302A1 (en)	2007-05-02
TWI359016B (en)	2012-03-01
ATE523505T1 (en)	2011-09-15
ECSP066941A (en)	2006-12-20
IL178672A (en)	2011-08-31
CA2563401A1 (en)	2005-11-10
SI1740569T1 (en)	2008-06-30
AU2005238144A1 (en)	2005-11-10
UY28868A1 (en)	2005-11-30
EP1864979B1 (en)	2011-09-07
DE502005002927D1 (en)	2008-04-03
AU2005238144B2 (en)	2010-08-26

Publication	Publication Date	Title
DK1789041T3 (en)	2008-09-08	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
DK1797042T3 (en)	2009-03-02	Indozolone derivatives as 11B-HSD1 inhibitors
DK1926722T3 (en)	2011-12-19	Substituted benzimidazoles as kinase inhibitors
DK1586319T3 (en)	2010-02-08	Thiadiazolidinones as GSK-3 inhibitors
DK1585749T3 (en)	2008-09-22	Diazepinoindole derivatives as kinase inhibitors
DK2094263T3 (en)	2013-12-02	2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS
ATE520671T1 (en)	2011-09-15	PYRIMIDINE-UREA DERIVATIVES AS KINASE INHIBITORS
DK1959951T3 (en)	2010-03-01	Heteroberl-substituted piperidine derivatives as L-CPT1 inhibitors
DK1663232T3 (en)	2008-02-04	Benzimidazole derivatives as human chymase inhibitors
ATE452631T1 (en)	2010-01-15	N-2-ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETAHYDROXYSTEROID DEHYDROGENASE INHIBITORS
DK2086939T3 (en)	2010-10-11	Pyridiacarboxamide as II-beta-HSDI inhibitors
DK1846394T3 (en)	2012-01-16	Pyrazolylaminopyridine derivatives suitable as kinase inhibitors
PT1586571E (en)	2008-09-08	DIPEPTIDIL-PEPTIDASE INHIBITORS
IS8578A (en)	2006-12-08	3- carbamoyl - 2-pyridone derivatives
DK2078001T3 (en)	2010-07-19	Diazepan-acetamide derivatives as selective 11-HSD1 inhibitors
DK2220070T3 (en)	2011-07-04	2-benzylpyridazine derivatives as Met kinase inhibitors
DK1725553T3 (en)	2008-08-18	Tetrahydropyridoindole derivatives
DK1828167T3 (en)	2014-10-20	Acrylamide derivatives as antibiotic agents
DK1740569T3 (en)	2008-06-02	Imidazole derivatives as TAF1α inhibitors
ATE383361T1 (en)	2008-01-15	PYRRAZOLOPYRIMIDE DERIVATIVES
ATE540935T1 (en)	2012-01-15	CHINAZOLINE DERIVATIVES
ATE417830T1 (en)	2009-01-15	SULFONYLBENZIMIDAZOLE DERIVATIVES
DK2049480T3 (en)	2014-01-20	2-arylindole derivatives as mPGES-1 inhibitors
DK1763517T3 (en)	2011-06-06	Pyrimidine derivatives as 11beta-HSD1 inhibitors
ZA200705068B (en)	2008-10-29	Hydantoin derivatives useful as metalloproteinase inhibitors